Colorectal Cancer

P=N/A, N=205, Completed, Dartmouth-Hitchcock Medical Center | N=382 --> 205

P2, N=128, Not yet recruiting, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

P1/2, N=933, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Dec 2026 --> Apr 2027

P2, N=214, Active, not recruiting, Gruppo Oncologico del Nord-Ovest | Trial completion date: Dec 2025 --> Mar 2026

P=N/A, N=30, Enrolling by invitation, Seoul St. Mary's Hospital

P=N/A, N=51, Not yet recruiting, Matteo Clavarezza | Trial completion date: Apr 2026 --> Jul 2026 | Initiation date: Sep 2025 --> Feb 2026

APG-115 effectively inhibits proliferation, induces apoptosis, and enhances radiosensitivity in p53 wild-type colorectal cancer. These findings support APG-115 as a promising therapeutic candidate for colorectal cancers retaining functional p53.

HPLC analysis revealed eight major phenolics, with gallic acid, chlorogenic acid, and daidzein being the predominant compounds...Molecular docking studies suggested that phenolic compounds effectively interact with the CDK4 active site, supporting their potential anticancer properties. These findings highlight B. aegyptiaca-derived SeNPs as promising candidates for biomedical applications.

Targeting surface ENO1 with HuL001, a first-in-class humanized antibody, significantly reduced glycolysis, decreased extracellular lactate accumulation, reprogrammed macrophage polarization and inhibited tumor growth and distant metastasis. Moreover, targeting surface ENO1 significantly increased the therapeutic response to radiotherapy and delayed tumor regrowth by increasing antitumoral M1 macrophages and cytotoxic CD8+ T cells infiltration within TME. These results indicated that targeting surface ENO1 remodeled the tumor microenvironment and provided better therapeutic effects to radiotherapy in poorly immunogenic colorectal cancer (CRC) and triple-negative breast cancer (TNBC).

We suggest that anti-B7-H3 immunotherapies might preferentially target cells from the microenvironment rather than tumor cells. This is particularly important for understanding the mode of action of the anti-B7-H3 antibody‒drug conjugate, which is currently being tested in clinical trials in several solid tumors.

The label-free CL immunoassay achieves an impressive limit of detection (LOD) of 22 fg/mL for CEA and 5.4 fg/mL for CA199, with broad linear ranges spanning over 5 orders of magnitude. The entire detection process is completed within 30 min, and the analysis of real serum samples demonstrates good recoveries.

Gene expression profiling demonstrated ≥ twofold changes in 51 genes, including downregulation of BAK1 and TRAF3, and upregulation of BIRC2, BIRC3, BIRC6, CASP8, TNFRSF8, TNFRSF11, and BOK. Collectively, these findings indicate that SFV exerts significant antitumor effects in colorectal cancer models and support its potential as a promising anticancer agent, warranting further mechanistic and translational investigation.